DrugPatentWatch Database Preview
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
« Back to Dashboard
CHS-828 is an investigational drug.
There have been 15 clinical trials for CHS-828. The most recent clinical trial was a Phase 3 trial, which was initiated on January 1st 2020.
The most common disease conditions in clinical trials are Psoriasis, Hyperemesis Gravidarum, and Arthritis, Rheumatoid. The leading clinical trial sponsors are Coherus Biosciences, Inc., Baxalta US Inc., and Daiichi Sankyo Co., Ltd.
There are eighteen US patents protecting this investigational drug and two hundred and sixty-two international patents.
Recent Clinical Trials for CHS-828
|Treatment Strategies in CHS||Canadian Institutes of Health Research (CIHR)||Phase 4|
|Treatment Strategies in CHS||University of Calgary||Phase 4|
|Improving Pain Control in Paraesophageal Hernia Repair: Intravenous Lidocaine Versus Placebo||Atrium Health||Phase 4|
Top disease conditions for CHS-828
Top clinical trial sponsors for CHS-828
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|CHS-828||Start Trial||Compounds and compositions for the inhibition of NAMPT||Forma TM, LLC (Watertown, MA) Genentech, Inc. (South San Francisco, CA)||Start Trial|
|CHS-828||Start Trial||Compounds and compositions for the inhibition of NAMPT||FORMA TM, LLC (Watertown, MA) Genentech, Inc. (South San Francisco, CA)||Start Trial|
|CHS-828||Start Trial||Methods and compositions for treatment of demyelinating diseases||Pathologica LLC (San Francisco, CA)||Start Trial|
|CHS-828||Start Trial||N-cyano-N'-pyridylguanidines as serotonin antagonists||Leo Pharmaceutical Products Ltd. (Ballerup, DK)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|